Advertisement

Reuters

Insys sees no change in estimated litigation costs

(Reuters) – Insys Therapeutics Inc said on Tuesday that it believed a previously estimated $150 million would be sufficient to cover expenses from an ongoing litigation related to the company’s sales practises. The...

Read More

For latest news and updates
Email-id is invalid